Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77560 | 0.94 | DPP8 (0.54) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL77561 | 0.94 | DPP8 (0.54) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL9142314 | 0.94 | DPP4 (0.54) | DPP4DPP8DPP9BLMKMT2A | |
| SCHEMBL2194678 | 0.93 | BMP1 (0.44) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL16468888 | 0.91 | DPP4 (0.42) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL3065570 | 0.87 | DPP4 (0.45) | DPP4DPP8DPP9CTSDBACE1 | |
| SCHEMBL2182616 | 0.87 | DPP4 (0.46) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL2182740 | 0.86 | BACE1 (0.45) | DPP4DPP8DPP9BMP1CTSD | |
| SCHEMBL2182958 | 0.86 | DPP4 (0.48) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL9273038 | 0.86 | DPP4 (0.48) | DPP4DPP8DPP9BLMGRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7919493-B2 | A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent | PHARMA MAR, S.A. (ES) | 2011-04-05 | — | — | US | disclosed |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | PHARMAMAR (ES) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | AREG, CD68, ASGR1 | DPP4 3764/4885DPP8 3068/4885DPP9 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.